PacBio’s latest announcement: The long and short of It
On the first day of American Society of Human Genetics meeting, PacBio rolls out new long and short-read sequencers…music group Maroon 5.
Facing regulatory block, Illumina’s $1.2B PacBio buyout falls apart
The Federal Trade Commission had accused Illumina of seeking to monopolize the market for next-generation sequencing in its effort to acquire Pacific Biosciences, originally announced in November 2018.
The Hidden Administrative Tasks Draining Small Practices
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
FTC moves to block Illumina’s $1.2B acquisition of PacBio
Federal regulators said they would seek to block the acquisition deal amid concerns that Illumina was seeking to eliminate PacBio as a competitor in the next-generation sequencing space.